RxDoctor Payments Data

Matthew Renner, OD

Optometrist · Fort Smith, ARNPI 1942229190

Payments from drug & device makers

$1,992in general payments, 2019–2025

Across 54 payments — averaging $36.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$680
  • Carl Zeiss Meditec, Inc.$266
  • AbbVie$220
  • Oyster Point Pharma, Inc.$128
  • Dompe US, Inc.$125
  • Tarsus Pharmaceuticals, Inc.$115
  • plus $458 from 10 others

What the payments were for

  • Food & beverage$1,96198%
  • Entertainment$312%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,992 in reported general payments places this provider in the 85th percentile of 442 optometrist providers in Arkansas.

See all optometrist providers in Arkansas

Medicare billing

Part B allowed, 2024
$184,805
Medicare patients
1,005
Services billed
2,185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine92$108,193
LumiganBimatoprost84$33,312
XdemvyLotilaner15$27,805
XiidraLifitegrast21$17,041
CombiganBrimonidine Tartrate/Timolol57$16,552
MieboPerfluorohexyloctane/Pf16$14,670
RocklatanNetarsudil Mesylat/Latanoprost25$14,447
VyzultaLatanoprostene Bunod15$8,608
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol17$4,950
Latanoprost706$4,841
SimbrinzaBrinzolamide/Brimonidine Tart15$3,676
Brimonidine Tartrate175$3,097
Prednisolone Acetate62$2,221
Travoprost13$2,200
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat183$2,015

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$220$158,057233 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$680$40,31952 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$115$27,80515 claims
Aerie Pharmaceuticals, Inc.Rocklatan$16$14,44725 claims
AlconSimbrinza$66$3,67615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 442 optometrist providers in Arkansas.

Other optometrist in Fort Smith

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →